Delving into the Latest Updates on Guangzhou Lion TCR Co., Ltd. with Synapse

Overview

Tags

Digestive System Disorders

Neoplasms

Infectious Diseases

Cell therapy

TCR-T Cell therapy

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Infectious Diseases	1

Top 5 Drug Type	Count

Cell therapy	1
TCR-T Cell therapy	1

Top 5 Target	Count

HBsAg	1

This is a open-label study to evaluate the safety and efficacy of autologous T-cells transfected with messenger ribonucleic acid (mRNA) encoding Hepatitis-B virus (HBV) antigen specific T cell receptor (TCR) in combination with nucleos(t)ide analogues (NAs) in HBeAg-positive and negative chronic hepatitis B patients.

Start Date31 Dec 2024

Sponsor / Collaborator

Changhai Hospital of Shanghai

[+1]

CTR20254209

/ Not yet recruitingPhase 1

GZL-016注射液治疗乙型肝炎病毒相关肝细胞癌的I/IIa期临床研究

[Translation] Phase I/IIa Clinical Study of GZL-016 Injection for the Treatment of Hepatitis B Virus-Related Hepatocellular Carcinoma

主要研究目的是评价研究产品在治疗乙型肝炎病毒（Hepatitis B virus， HBV）相关肝细胞癌（ Hepatocellular carcinoma， HCC）患者中的安全性、耐受性、药代动力学、药效学和初步疗效。研究将分为两个部分，剂量递增研究和剂量扩展研究。确定最大耐受剂量（MTD）或II期推荐剂量（RP2D）。

[Translation]

The primary objective of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the investigational product in the treatment of patients with hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC). The study will be conducted in two phases: a dose-escalation study and a dose-expansion study. The maximum tolerated dose (MTD) or the Phase II recommended dose (RP2D) will be determined.

Start Date-

Sponsor / Collaborator

Guangzhou Lion TCR Co., Ltd.

100 Clinical Results associated with Guangzhou Lion TCR Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Guangzhou Lion TCR Co., Ltd.

Login to view more data

100 Deals associated with Guangzhou Lion TCR Co., Ltd.

Login to view more data

100 Translational Medicine associated with Guangzhou Lion TCR Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 06 Feb 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Phase 1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

LioCyx-M ( HBsAg )	Hepatitis B, Chronic More	Phase 1
in vivo Universal cell therapy(Guangzhou Lion TCR/The Shenzhen Institutes of Advanced Technology)	Neoplasms More	Discovery